KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Leases: 2019-2024

Historic Current Leases for Pacira BioSciences (PCRX) over the last 6 years, with Dec 2024 value amounting to $8.9 million.

  • Pacira BioSciences' Current Leases rose 6.06% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 6.06%. This contributed to the annual value of $8.9 million for FY2024, which is 0.98% up from last year.
  • Per Pacira BioSciences' latest filing, its Current Leases stood at $8.9 million for FY2024, which was up 0.98% from $8.8 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Current Leases ranged from a high of $9.1 million in FY2022 and a low of $7.4 million during FY2020.
  • Moreover, its 3-year median value for Current Leases was $8.9 million (2024), whereas its average is $8.9 million.
  • As far as peak fluctuations go, Pacira BioSciences' Current Leases spiked by 50.46% in 2020, and later decreased by 3.51% in 2023.
  • Pacira BioSciences' Current Leases (Yearly) stood at $7.4 million in 2020, then climbed by 6.28% to $7.9 million in 2021, then grew by 15.59% to $9.1 million in 2022, then fell by 3.51% to $8.8 million in 2023, then grew by 0.98% to $8.9 million in 2024.